

Harald Hegen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3752243/publications.pdf>

Version: 2024-02-01

114
papers

3,047
citations

185998

28
h-index

182168

51
g-index

116
all docs

116
docs citations

116
times ranked

3642
citing authors

#	ARTICLE	IF	CITATIONS
1	Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. <i>Journal of Neuroinflammation</i> , 2011, 8, 184.	3.1	379
2	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1013-1024.	1.4	249
3	International multicenter examination of MOG antibody assays. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	180
4	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. <i>Brain</i> , 2015, 138, 918-931.	3.7	147
5	Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1802-1809.	1.4	133
6	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. <i>Brain</i> , 2018, 141, 1085-1093.	3.7	115
7	Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1533-1538.	1.4	92
8	Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: A multicenter study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 502-510.	1.4	87
9	Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients. <i>Journal of Neuroinflammation</i> , 2022, 19, 19.	3.1	82
10	Upper reference limits for cerebrospinal fluid total protein and albumin quotient based on a large cohort of control patients: implications for increased clinical specificity. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 285-92.	1.4	67
11	Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 196-203.	1.4	67
12	Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study. <i>PLoS ONE</i> , 2016, 11, e0158978.	1.1	56
13	Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1241-1248.	1.4	56
14	“No evidence of disease activity”™ “ is it an appropriate surrogate in multiple sclerosis?. <i>European Journal of Neurology</i> , 2018, 25, 1107.	1.7	55
15	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 912-923.	1.4	52
16	Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria. <i>Multiple Sclerosis Journal</i> , 2020, 26, 69-78.	1.4	51
17	Recent developments in MOG-IgG associated neurological disorders. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642094513.	1.5	45
18	Adult CSF total protein upper reference limits should be age-partitioned and significantly higher than 0.45Åg/L: a systematic review. <i>Journal of Neurology</i> , 2019, 266, 616-624.	1.8	41

#	ARTICLE	IF	CITATIONS
19	Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. <i>Multiple Sclerosis Journal</i> , 2014, 20, 577-587.	1.4	40
20	Muscle involvement in SARS-CoV-2 infection. <i>European Journal of Neurology</i> , 2021, 28, 3411-3417.	1.7	40
21	Multiple sclerosis and COVID-19: How many are at risk?. <i>European Journal of Neurology</i> , 2021, 28, 3369-3374.	1.7	37
22	Macular ganglion cell inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 684-694.	1.4	36
23	Cytokine profiles show heterogeneity of interferon- γ response in multiple sclerosis patients. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e202.	3.1	34
24	Admission diagnoses of patients later diagnosed with autoimmune encephalitis. <i>Journal of Neurology</i> , 2019, 266, 124-132.	1.8	34
25	Physiological evidence for diversification of IFN γ - and IFN γ -mediated response programs in different autoimmune diseases. <i>Arthritis Research and Therapy</i> , 2016, 18, 49.	1.6	32
26	Peripapillary retinal nerve fibre layer thinning rate as a biomarker discriminating stable and progressing relapsing remitting multiple sclerosis. <i>European Journal of Neurology</i> , 2019, 26, 865-871.	1.7	32
27	Persistency of neutralizing antibodies depends on titer and interferon-beta preparation. <i>Multiple Sclerosis Journal</i> , 2012, 18, 610-615.	1.4	31
28	Change of olfactory function as a marker of inflammatory activity and disability progression in MS. <i>Multiple Sclerosis Journal</i> , 2019, 25, 267-274.	1.4	29
29	To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101908.	0.9	29
30	Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study. <i>PLoS ONE</i> , 2017, 12, e0174005.	1.1	29
31	Quantitation of intrathecal immunoglobulin synthesis – a new empirical formula. <i>European Journal of Neurology</i> , 2016, 23, 713-721.	1.7	28
32	COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry. <i>PLoS ONE</i> , 2021, 16, e0255316.	1.1	27
33	Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study. <i>PLoS ONE</i> , 2017, 12, e0182462.	1.1	26
34	Kappa-Free Light Chains in CSF Predict Early Multiple Sclerosis Disease Activity. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	26
35	Free light chains in the cerebrospinal fluid. Comparison of different methods to determine intrathecal synthesis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1574-1586.	1.4	25
36	Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1682-1690.	1.4	25

#	ARTICLE	IF	CITATIONS
37	Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2209-2218.	1.4	25
38	The clinical significance of single or double bands in cerebrospinal fluid isoelectric focusing. A retrospective study and systematic review. <i>PLoS ONE</i> , 2019, 14, e0215410.	1.1	23
39	Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon- β . <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1803-1819.	1.5	22
40	Validation of inter-eye difference thresholds in optical coherence tomography for identification of optic neuritis in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102403.	0.9	22
41	Cerebrospinal fluid free light chains as diagnostic biomarker in neuroborreliosis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 1383-1391.	1.4	21
42	Serum glucose adjusted cut-off values for normal cerebrospinal fluid/serum glucose ratio: implications for clinical practice. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 1335-40.	1.4	20
43	Adult CSF total protein: Higher upper reference limits should be considered worldwide. A web-based survey. <i>Journal of the Neurological Sciences</i> , 2019, 396, 48-51.	0.3	20
44	Smelling multiple sclerosis: Different qualities of olfactory function reflect either inflammatory activity or neurodegeneration. <i>Multiple Sclerosis Journal</i> , 2020, 26, 57-68.	1.4	20
45	Transient impairment of olfactory threshold in acute multiple sclerosis relapse. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 23, 74-77.	0.9	19
46	Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102155.	0.9	18
47	Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score. <i>European Journal of Neurology</i> , 2021, 28, 1609-1616.	1.7	18
48	Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases. <i>Frontiers in Immunology</i> , 2020, 11, 1188.	2.2	16
49	Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	16
50	Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732096634.	0.5	15
51	Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients. <i>Drugs</i> , 2016, 76, 1421-1445.	4.9	14
52	Impairment of odor discrimination and identification is associated with disability progression and gray matter atrophy of the olfactory system in MS. <i>Multiple Sclerosis Journal</i> , 2020, 26, 706-715.	1.4	14
53	Bi-insular cortical involvement in anti-NMDA-receptor encephalitis – a case report. <i>BMC Neurology</i> , 2016, 16, 130.	0.8	12
54	Cerebrospinal fluid:serum glucose ratio in the ventricular and lumbar compartments: implications for clinical practice. <i>European Journal of Neurology</i> , 2018, 25, 373-379.	1.7	12

#	ARTICLE	IF	CITATIONS
55	Cerebrospinal fluid protein in Guillain-Barré syndrome: Need for age-dependent interpretation. <i>European Journal of Neurology</i> , 2021, 28, 965-973.	1.7	12
56	Cerebrospinal Fluid Findings in 541 Patients With Clinically Isolated Syndrome and Multiple Sclerosis: A Monocentric Study. <i>Frontiers in Immunology</i> , 2021, 12, 675307.	2.2	12
57	Comparing humoral immune response to SARS-CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study. <i>European Journal of Neurology</i> , 2022, 29, 1538-1544.	1.7	12
58	Rethinking the importance of paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis: They do matter. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 9, 150-154.	0.9	11
59	Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS. <i>BMC Medicine</i> , 2020, 18, 298.	2.3	11
60	Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 2037-2045.	1.7	10
61	New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab. <i>Frontiers in Neurology</i> , 2020, 11, 579438.	1.1	9
62	Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis—from diagnosis to prediction of disease activity. <i>Wiener Medizinische Wochenschrift</i> , 2022, 172, 337-345.	0.5	9
63	Long-term outcome after COVID-19 infection in multiple sclerosis: A nationwide multicenter matched-control study. <i>European Journal of Neurology</i> , 2022, 29, 3050-3060.	1.7	9
64	Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial. <i>Journal of Neuroimmunology</i> , 2015, 287, 98-105.	1.1	8
65	Combined evaluation of personality, risk and coping in MS patients: A step towards individualized treatment choice – The PeRiCoMS-Study I. <i>Journal of the Neurological Sciences</i> , 2017, 376, 71-75.	0.3	7
66	Conversion and reversion of anti-John Cunningham virus antibody serostatus: A prospective study. <i>Brain and Behavior</i> , 2019, 9, e01332.	1.0	7
67	Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for <i>Borrelia burgdorferi</i> . <i>PLoS ONE</i> , 2020, 15, e0239453.	1.1	7
68	Serum neurofilament light levels correlate with change of olfactory function in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731988598.	0.5	6
69	Serum Cotinine Does Not Predict Neutralizing Antibodies Against Interferon Beta in an Austrian MS Cohort. <i>Journal of Interferon and Cytokine Research</i> , 2016, 36, 667-670.	0.5	5
70	Persistency of Neutralizing Anti-Interferon- γ 2 Antibodies in Patients with Multiple Sclerosis Treated with Subcutaneous Interferon- γ 2 Depends on Antibody Titers, IgG Subclasses, and Affinity Maturation. <i>Journal of Interferon and Cytokine Research</i> , 2017, 37, 317-324.	0.5	5
71	Estimating Risk of Multiple Sclerosis Disease Reactivation in Pregnancy and Postpartum: The VIPRiMS Score. <i>Frontiers in Neurology</i> , 2021, 12, 766956.	1.1	5
72	Retinal layer thinning as a biomarker of long-term disability progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1871-1880.	1.4	5

#	ARTICLE	IF	CITATIONS
73	Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years. <i>Scientific Reports</i> , 2021, 11, 23317.	1.6	4
74	Alemtuzumab induced hemodynamic change in relapsing multiple sclerosis occurs independent of corticosteroid premedication – a retrospective multicentre study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103810.	0.9	4
75	Cerebrospinal fluid biomarkers in bacterial meningitis / Biomarker im Liquor cerebrospinalis bei bakterieller Meningitis. <i>Laboratoriums Medizin</i> , 2009, 33, 321-331.	0.1	3
76	Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking. <i>Laboratoriums Medizin</i> , 2010, 34, 1-12.	0.1	3
77	High-dose intravenous interferon-beta in multiple sclerosis patients with high-titer neutralizing antibodies (HINABS II) – A pilot study. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 220-226.	0.9	3
78	Vascular diseases and bleedings. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 146, 207-236.	1.0	3
79	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and Varicella Zoster Virus Infection - Frequency of an Association. <i>Frontiers in Immunology</i> , 2021, 12, 769653.	2.2	3
80	Olfactory threshold predicts treatment response in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1541-1552.	1.4	3
81	Sudomotor dysfunction in people with neuromyelitis optica spectrum disorders. <i>European Journal of Neurology</i> , 2022, 29, 2772-2780.	1.7	3
82	Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: A prospective multicenter study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 65, 104009.	0.9	3
83	Smoking is not associated with higher prevalence of JC virus in MS patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 907-910.	1.3	2
84	A Survey of Cerebrospinal Fluid Total Protein Upper Limits in Canada: Time for an Update?. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 283-286.	0.3	2
85	Inner nuclear layer and olfactory threshold are interlinked and reflect inflammatory activity in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732094573.	0.5	2
86	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. <i>PLoS ONE</i> , 2020, 15, e0234333.	1.1	2
87	Functional Recovery in Autoimmune Encephalitis: A Prospective Observational Study. <i>Frontiers in Immunology</i> , 2021, 12, 641106.	2.2	2
88	Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis – The PaSiMS II study. <i>PLoS ONE</i> , 2017, 12, e0181458.	1.1	2
89	Implementation study of the 2021 German guideline for diagnosis and treatment of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 57, 103434.	0.9	2
90	Natalizumab treatment during pregnancy in multiple sclerosis – clinical and bioethical aspects of an ongoing debate. <i>Wiener Medizinische Wochenschrift</i> , 2022, , 1.	0.5	2

#	ARTICLE	IF	CITATIONS
91	Caspr2 antibodies in herpes simplex encephalitis: an extension of the spectrum of virus induced autoimmunity? â€“ A case report. BMC Neurology, 2022, 22, 131.	0.8	2
92	Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis. Frontiers in Immunology, 2018, 9, 2435.	2.2	1
93	Utility of Two-Dimensional Difference Gel Electrophoresis in Diagnosis of Multiple Sclerosis. Diagnostics, 2018, 8, 44.	1.3	1
94	Effects of actual and imagined music-cued gait training on motor functioning and brain activity in people with multiple sclerosis: protocol of a randomised parallel multicentre trial. BMJ Open, 2022, 12, e056666.	0.8	1
95	German guideline for diagnosis and treatment of multiple sclerosis â€“ a survey focusing neurologists in daily practise. Multiple Sclerosis and Related Disorders, 2022, 63, 103828.	0.9	1
96	Endothelin and nitric oxide as cerebrospinal fluid biomarkers for cerebral vasospasm following subarachnoid haemorrhage / Endothelin und NO als Liquorbiomarker fÃ¼r cerebralen Vasospasmus nach Subarachnoidalblutung. Laboratoriums Medizin, 2010, 34, 343-347.	0.1	0
97	A6.12â€¦Physiological evidence for diversification of IFNÎ±- and IFNÎ²-mediated response programs in different autoimmune diseases. Annals of the Rheumatic Diseases, 2016, 75, A52.1-A52.	0.5	0
98	Autoantibodies against neuronal surface proteins in spontaneous subarachnoid and intracerebral haemorrhage. BMC Neurology, 2018, 18, 89.	0.8	0
99	Dataset for worldwide survey of cerebrospinal total protein upper reference values. Data in Brief, 2019, 23, 103760.	0.5	0
100	Transverse myelitis as a rare presentation of antiphospholipid-antibody-associated disorders. Multiple Sclerosis and Related Disorders, 2020, 45, 102405.	0.9	0
101	Commentary to â€œLetter to the editor: To treat or not to treat study - Comparative group inclusion considerationsâ€œfor multiple sclerosis and related disorders. Multiple Sclerosis and Related Disorders, 2020, 40, 101975.	0.9	0
102	Oligoclonal Bands: Isoelectric Focusing and Immunoblotting, and Determination of Î² Free Light Chains in the Cerebrospinal Fluid. Neuromethods, 2021, , 29-54.	0.2	0
103	SARS-CoV2 infection as a potential trigger for severe relapse in a patient with multiple sclerosis who stopped disease modifying treatment due to COVID-19 pandemic. Neuroimmunology Reports, 2021, 1, 100005.	0.2	0
104	Recovery of Chronic Inflammatory Demyelinating Polyneuropathy on Treatment With Ocrelizumab in a Patient With Co-Existing Multiple Sclerosis. Journal of Central Nervous System Disease, 2022, 14, 117957352210848.	0.7	0
105	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0
106	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0
107	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0
108	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0

#	ARTICLE	IF	CITATIONS
109	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0
110	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0
111	Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi. , 2020, 15, e0239453.		0
112	Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi. , 2020, 15, e0239453.		0
113	Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi. , 2020, 15, e0239453.		0
114	Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi. , 2020, 15, e0239453.		0